NEW YORK – June 15, 2022 – NOVOS, a company that develops science-based products to slow down aging, announced results of two studies demonstrating that the combination of ingredients in its products, NOVOS Core and NOVOS Boost, protect against DNA damage and cellular aging (senescence).
A study found that a combination of the 12 ingredients in NOVOS Core and the nicotinamide mononucleotide (NMN) in NOVOS Boost significantly protects cells against DNA damage over a wide dose range.
The study was done by Ichor Life Sciences, an independent third-party US-based lab specialized in DNA damage, cellular senescence, and aging.
In the study, HUVEC cells (human umbilical vein endothelial cells) were treated with the 13-ingredient NOVOS formulation and then irradiated. Irradiation typically causes pronounced DNA damage. However, the cells expos to NOVOS before irradiation had significantly less DNA damage after being exposed to radiation, as measured via 8-hydroxy-2′-deoxyguanosine (8-OHdG or 8-oxodG) levels. 8-OHdG is a measure of oxidative DNA damage. When DNA gets damaged, 8-OHdG is formed. Treating cells with NOVOS was able to reduce DNA damage as measured by 8-OHdG by up to 77% and on average 68% compared to controls (figure 1).
Irradiated cells treated with the NOVOS formulation (orange bars; different concentrations of NOVOS ranging from 50.0uM to 0.2 uM) showed significantly less DNA damage (as measured by 8-OHdG levels; the lower the bars, the less DNA damage) versus irradiated cells that weren’t treated with the NOVOS formulation (gray bars).
Researchers demonstrated that the NOVOS formulation protects against DNA damage over a wide range of doses, an effect mediated by DNA protective effects of multiple NOVOS ingredients at different doses and synergy between ingredients.
Another study was conducted at the Ageing Research Laboratories at Newcastle University (UK), specialized in cellular senescence and aging. The study found that the combination of multiple NOVOS ingredients could help the body better deal with senescent cells. The study was completed under the guidance of Dr. Thomas von Zglinicki, Professor for Cell Gerontology at Newcastle University.
Senescent cells occur during aging and play an important role in the aging process. These cells accumulate various forms of damage, including DNA and epigenetic damage, and secrete substances that harm healthy surrounding cells.
Research has shown that countering senescent cells using senostatic drugs (which suppress senescent cells) can support the body to deal better with aging. In the UK study, researchers using cell size as marker for the senescent phenotype found that specific NOVOS ingredients had a senostatic effect, while not impacting normal, non-senescent cells.
A senostatic effect comprising a reduction in senescent cell size has also been observed with rapamycin, a prescription drug associated with increased longevity in multiple animal models.
Normal non-senescent cells were not impacted by the NOVOS formulation, demonstrating that specific NOVOS ingredients used in a synergistic combination can impact senescent cells while not impacting healthy cells — a common pitfall of “senolytic” molecules which seek to destroy senescent cells.
“As a data-centric, science-driven company, these early results are a great step forward for NOVOS, further contributing to the validation of our formulations that improve human longevity by targeting the biological causes of aging,” said Chris Mirabile, founder and CEO of NOVOS. “We look forward to seeing results from additional studies in our pursuit of effective longevity formulations validated by science.”
To learn more about NOVOS, its products, and the ingredients analyzed in these studies, visit www.novoslabs.com.
NOVOS’ mission is to help people live longer, healthier lives by developing science-based products that slow down aging and is the first company to address 10 hallmarks of aging. NOVOS is a global team of longevity scientists, MDs, and practitioners. (www.novoslabs.com).
A portion of the profits and equity from NOVOS are being donated to nonprofits working in the longevity science space, which includes us here at Lifespan.io.
Our Vice President, Dr. Oliver Medvedik, is also a scientific consultant, putting him in good company with Dr. Joao Pedro Magalhaes, Dr. Pamela Maher, Dr. Avi Rosenbaum, and Dr. Matt Kaeberlein, names with whom regular readers may be familiar.